DE4017979A1 - Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid - Google Patents
Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acidInfo
- Publication number
- DE4017979A1 DE4017979A1 DE19904017979 DE4017979A DE4017979A1 DE 4017979 A1 DE4017979 A1 DE 4017979A1 DE 19904017979 DE19904017979 DE 19904017979 DE 4017979 A DE4017979 A DE 4017979A DE 4017979 A1 DE4017979 A1 DE 4017979A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- low cholesterol
- cholesterol
- medicine
- arachidonic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 18
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 11
- 239000002253 acid Substances 0.000 title claims abstract description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 150000008104 phosphatidylethanolamines Chemical class 0.000 title claims abstract description 7
- -1 cholesterol lipid Chemical class 0.000 title claims abstract 4
- 239000003814 drug Substances 0.000 title claims abstract 4
- 235000005911 diet Nutrition 0.000 title abstract description 3
- 230000000378 dietary effect Effects 0.000 title abstract description 3
- 235000016709 nutrition Nutrition 0.000 title abstract description 3
- 230000035764 nutrition Effects 0.000 title abstract description 3
- 125000005456 glyceride group Chemical group 0.000 title description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 14
- 150000002632 lipids Chemical class 0.000 claims abstract description 10
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 7
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 6
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract 8
- 150000007513 acids Chemical class 0.000 claims abstract 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000032683 aging Effects 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims abstract 2
- 230000035699 permeability Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 210000000987 immune system Anatomy 0.000 abstract description 2
- 208000020016 psychiatric disease Diseases 0.000 abstract description 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Die Erfindung bezieht sich auf Lipid-Zusammensetzungen und deren Einsatz auf dem medizinischen Sektor bzw. dem Bereich der diätetischen Ernährung.The invention relates to lipid compositions and their Use in the medical sector or in the field of dietary nutrition.
Es ist eine Zusammensetzung mit einer Lipidfraktion natürlicher Herkunft bekannt (EU-PS 00 74 251), die 40-80 Gew.-% Glyceride, 3-5 Gew.-% Cholesterin, 10-30 Gew.-% Lecithin (Phosphatidylcholin), 5-15 Gew.-% Phosphatidylethanolamin und 2-5 Gew.-% negativ geladene Phospholipoide enthält, wobei das Verhältnis von ungesättigten zu gesättigten Fettsäuren wenigstens 1 : 1 beträgt.It is a composition with a natural lipid fraction Origin known (EU-PS 00 74 251), the 40-80 wt .-% Glycerides, 3-5% by weight cholesterol, 10-30% by weight lecithin (Phosphatidylcholine), 5-15% by weight phosphatidylethanolamine and Contains 2-5 wt .-% negatively charged phospholipids, which Ratio of unsaturated to saturated fatty acids is at least 1: 1.
Diese Zusammensetzung hat einen weiten Einsatzbereich gefunden, und zwar immer dann, wenn es um Zellmembran bezogene Erkrankungen, Störungen, Phänomene oder Syndrome ging.This composition has found a wide range of uses, and always when it comes to cell membrane related Diseases, disorders, phenomena or syndromes went.
In der Zwischenzeit haben sich jedoch neuere Erkenntnisse der Wirkungsweise des Zellmechanismus, insbesondere im Zusammenhang mit dem Fusionsprozeß für lipidummantelte Viren und hinsichtlich der Membran-Rezeptor Interaktionen ergeben, und daher hatten sich die Erfinder die Aufgabe gestellt, eine Zusammensetzung aus Phospholipiden und anderen Bestandteilen so zu formulieren, daß noch bessere Resultate im Zusammenhang mit der Behandlung von Viruserkrankungen, Fehlfunktionen des Immunsystems, Allergien, Störungen des Geisteszustandes, Drogenentzugserscheinungen und dergleichen erzielt werden können.In the meantime, however, newer knowledge of the Mode of action of the cell mechanism, especially in connection with the fusion process for lipid-coated viruses and regarding the membrane receptor gave interactions, and therefore had the inventors set themselves the task of making up a composition Formulate phospholipids and other ingredients so that even better results related to the treatment of Viral diseases, malfunctions of the immune system, allergies, Mental disorders, drug withdrawal symptoms and the like can be achieved.
Erreicht wird dies durch Zusammensetzungen, so wie sie in den Ansprüchen 1 bis 3 wiedergegeben sind und Applikationen, so wie sie in den Ansprüchen 4 und 5 präzisiert sind.This is achieved through compositions such as those in the Claims 1 to 3 are reproduced and applications, such as they are specified in claims 4 and 5.
Versuche mit den folgenden Zusammensetzungen haben bei der Ermittlung der HIV-1 Infizierbarkeit hervorragende Ergebnisse gebracht.Experiments with the following compositions have in the Determination of HIV-1 Infectability Excellent Results brought.
Cholesterinfreie Phospholipid-Zusammensetzung mit 20 Gew.-% Phosphatidylcholin, 6 Gew.-% Phosphatidylethanolamin, 70 Gew.-% Triglyceride und mit 4 Gew.-% Arachidonsäure (C20 : 4w-6) und Docosahexaenolsäure (C22 : 6w-6).Cholesterol-free phospholipid composition with 20% by weight Phosphatidylcholine, 6% by weight phosphatidylethanolamine, 70 % By weight of triglycerides and with 4% by weight of arachidonic acid (C20: 4w-6) and docosahexaenolic acid (C22: 6w-6).
(Cholesterinfrei oder -arm im Sinne dieser Anmeldung bedeutet weniger als 0,5 Gew.-% Cholesterin).(Cholesterol free or low in the sense of this application means less than 0.5 wt% cholesterol).
Phospholipid-Zusammensetzung mit 20 Gew.-% Phosphatidylcholin, 20 Gew.-% Phosphatidylethanolamin, 5-10 Gew.-% Triglyceride, 5 Gew.-% Cholesterin und 8 Gew.-% Arachidonsäure (C20 : 4w-6) und Docosahexaenolsäure (C22 : 6w-6), sowie sonstige zuvor nicht genannte Bestandteile.Phospholipid composition with 20% by weight Phosphatidylcholine, 20% by weight phosphatidylethanolamine, 5-10% by weight triglycerides, 5% by weight cholesterol and 8% by weight Arachidonic acid (C20: 4w-6) and docosahexaenolic acid (C22: 6w-6), as well as other previously not mentioned Components.
Die Infizierbarkeit wurde in % der infizierten Zellen ermittelt,
indem wie folgt vorgegangen wurde:
In Zellkulturen wurden die Zusammensetzungen nach Beispiel 1 und
2 vermischt und mit einem HIV-1 Virus inkubiert. Es wurde das
Auftreten von Virus-Antigenen in den Zellen ermittelt, wobei auf
die intrazellulare HIV-1-Replikation geschlossen wurde, die
wiederum mit der Methode der indirekten Immunofluoreszenz mit
HIV-1 Antikörpern bestimmt wurde. Entsprechend wurde mit anderen
Phospholipid-Zusammensetzungen vorgegangen.Infectability was determined in% of the infected cells by doing the following:
The compositions according to Examples 1 and 2 were mixed in cell cultures and incubated with an HIV-1 virus. The occurrence of virus antigens in the cells was determined, concluding from the intracellular HIV-1 replication, which in turn was determined by the indirect immunofluorescence method with HIV-1 antibodies. The same procedure was followed with other phospholipid compositions.
Als Ergebnisse wurden für die Infizierbarkeit Werte von unter 65% nach 5 bis 6 Wochen gemessen, also Werte, die andere Phospholipid-Zusammensetzungen außerhalb des Bereichs der vorliegenden Erfindung nicht erreichen. Diese Werte liegen nämlich über 95 Gew.-%.The results for infectability were below 65% measured after 5 to 6 weeks, i.e. values that are different Phospholipid compositions outside the range of not achieve the present invention. These values lie namely over 95% by weight.
Es wurde ebenfalls überprüft, inwieweit das in den lipidbehandelten Zellen produzierte Virus infektiös ist.It was also checked to what extent this was in the virus produced by lipid-treated cells is infectious.
Hierbei wurde so vorgegangen, daß der zellfreie Überstand aus zuvor infizierten lipidbehandelten Zellkulturen separiert wurde und den gleichen, jedoch nicht infizierten, nicht lipidbehandelten Zellen zugegeben wurde. Sodann wurde, wie bereits angegeben, die intrazellulare HIV-1-Replikation ermittelt und wiederum in % der infizierten Zellen angegeben. Hierbei wurden Versuche an einer Vielzahl von Phospholipid- Zusammensetzungen gemacht und insbesondere an folgender cholesterinfreien Zusammensetzung.The procedure was such that the cell-free supernatant was removed previously infected lipid-treated cell cultures were separated and the same, but not infected, not lipid-treated cells was added. Then how previously stated intracellular HIV-1 replication determined and again in% of the infected cells. Tests on a variety of phospholipid Compositions made and in particular the following cholesterol free composition.
94 Gew.-% reines Phosphatidylcholin, 6 Gew.-% Phosphatidylethanolamin, 70 Gew.-% Triglyceride enthaltend und mit 4 Gew.-% Arachidonsäure (C20 : 4w-6) und 5 Gew.-% Docosahexaenolsäure (C22 : 6w-6).94% by weight pure phosphatidylcholine, 6% by weight Phosphatidylethanolamine, containing 70 wt .-% triglycerides and with 4% by weight arachidonic acid (C20: 4w-6) and 5% by weight Docosahexaenolic acid (C22: 6w-6).
Beim Beispiel 3 wurden im Bereich von 0 bis 6 Wochen bei Inkubation mit zellfreiem Überstand keine infizierten Zellen festgestellt, so daß geschlossen werden kann, daß Zellen, die mit einer Zusammensetzung nach Beispiel 3 behandelt worden sind und durch HIV-1 Viren infiziert worden sind, kein intaktes Virus ausschleusen, das heißt, daß der zellfreie Überstand kein infizierendes Material enthält. Example 3 was in the range of 0 to 6 weeks Incubation with cell-free supernatant, no infected cells found so that it can be concluded that cells that have been treated with a composition according to Example 3 and have been infected by HIV-1 viruses, not an intact virus discharge, which means that the cell-free supernatant is not contains infectious material.
Vielversprechend sind Kombinationen von Zusammensetzungen, die sowohl aus Bestandteilen des Beispiels 1 oder des Beispiels 2, in Kombination mit dem Beispiel 3 bestehen.Combinations of compositions are promising both from components of example 1 or example 2, in combination with Example 3.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904017979 DE4017979A1 (en) | 1990-06-05 | 1990-06-05 | Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904017979 DE4017979A1 (en) | 1990-06-05 | 1990-06-05 | Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE4017979A1 true DE4017979A1 (en) | 1991-12-12 |
Family
ID=6407811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904017979 Ceased DE4017979A1 (en) | 1990-06-05 | 1990-06-05 | Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4017979A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0524796A1 (en) * | 1991-07-24 | 1993-01-27 | Scotia Holdings Plc | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS |
| WO1994001089A1 (en) * | 1992-07-08 | 1994-01-20 | Dianorm-Geräte G. Maierhofer | Liposomes, method of preparing them and their use in the preparation of drugs |
| EP0733360A2 (en) * | 1992-11-26 | 1996-09-25 | Scotia Holdings Plc | Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids |
| EP0767666A1 (en) * | 1994-08-10 | 1997-04-16 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
| WO2004050077A1 (en) * | 2002-12-05 | 2004-06-17 | Proyecto Empresarial Brudy, S.L. | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0074251A1 (en) * | 1981-09-04 | 1983-03-16 | Yeda Research And Development Company, Ltd. | Novel lipid fraction, its preparation and pharmaceutical compositions containing same |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| WO1989003684A1 (en) * | 1987-10-30 | 1989-05-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-hiv agent |
| US4841023A (en) * | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
-
1990
- 1990-06-05 DE DE19904017979 patent/DE4017979A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0074251A1 (en) * | 1981-09-04 | 1983-03-16 | Yeda Research And Development Company, Ltd. | Novel lipid fraction, its preparation and pharmaceutical compositions containing same |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| US4841023A (en) * | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
| WO1989003684A1 (en) * | 1987-10-30 | 1989-05-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-hiv agent |
Non-Patent Citations (1)
| Title |
|---|
| CA 106: 131277a, 1987 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0524796A1 (en) * | 1991-07-24 | 1993-01-27 | Scotia Holdings Plc | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS |
| WO1994001089A1 (en) * | 1992-07-08 | 1994-01-20 | Dianorm-Geräte G. Maierhofer | Liposomes, method of preparing them and their use in the preparation of drugs |
| EP0733360A2 (en) * | 1992-11-26 | 1996-09-25 | Scotia Holdings Plc | Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids |
| EP0733360A3 (en) * | 1992-11-26 | 1996-10-02 | Scotia Holdings Plc | Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids |
| EP0767666A1 (en) * | 1994-08-10 | 1997-04-16 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
| EP0767666A4 (en) * | 1994-08-10 | 1998-10-07 | Rogosin Inst | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
| WO2004050077A1 (en) * | 2002-12-05 | 2004-06-17 | Proyecto Empresarial Brudy, S.L. | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
| CN100355421C (en) * | 2002-12-05 | 2007-12-19 | 布鲁迪企划有限公司 | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
| EA009711B1 (en) * | 2002-12-05 | 2008-02-28 | Проекто Эмпресариал Бруди, С.Л. | Method for the treatment of lipodystrophy in a mammal |
| US8202906B2 (en) | 2002-12-05 | 2012-06-19 | Proyecto Empresarial Brudy, S.L. | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3926658C2 (en) | Fatty acid composition | |
| DE2938807C2 (en) | Fat emulsion that can be administered intravenously | |
| DE3752165T2 (en) | Removal of fat-soluble reagents from biological materials by extraction with natural oils or synthetic substitutes | |
| EP1838171B1 (en) | Production and use of an antioxidant extract from crypthecodinium sp | |
| DE2834308C2 (en) | Process for the elimination of water from a colloidal liposome dispersion | |
| DE68911103T2 (en) | Use of fatty acids for the treatment of myalgic encephalomyelitis. | |
| DE2718797C3 (en) | Process for the production of flowable oil-containing purified phosphatidylcholine | |
| DE69815581T2 (en) | Process for the production of vegetable lysolecithins | |
| DE2905979C2 (en) | Use of acetylated, distilled monoglycerides for the treatment of lipid metabolic disorders in humans | |
| DE4133694A1 (en) | USE OF AN EMULSION FOR PREPARING A MEDICAMENT FOR I.V. ADMINISTRATION FOR THE TREATMENT OF SKIN DISEASES | |
| DE69625616T3 (en) | LIPID EMULSIONS WITH OPTIMIZED HYDROLYSIS AND THEIR USE | |
| DE69426114T2 (en) | METHOD FOR PRODUCING HIGH PURITY PHOSPHATIDYLCHOLINS | |
| DE69327539T2 (en) | PHOSPHATIDYLCHOLINE AND METHOD FOR THE PRODUCTION THEREOF | |
| DE3334323A1 (en) | PROPHYLACTIC SUBSTANCE OR COMPOSITION | |
| DE2943885A1 (en) | FAT EMULSION FOR INTRAVENOOSE INJECTION | |
| DE4017979A1 (en) | Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid | |
| DE10361667A1 (en) | Novel fat powder | |
| EP0339382B1 (en) | Process for deodorizing mixtures of fatty acid esters | |
| DE2147327C3 (en) | Process for obtaining purified, non-acylatable phosphatide | |
| EP0604806A2 (en) | Composition containing phospholipids | |
| DE68926162T2 (en) | Glycerophospholipid preparation with increased wetting effect | |
| DE4000084A1 (en) | INTRAVENOES APPLICABLE PHARMACEUTICAL PREPARATION OF ET18-OCH (DOWN ARROW) 3 (DOWN ARROW) | |
| AT390374B (en) | METHOD FOR PASTEURIZING PLASMA PROTEIN AND PLASMA PROTEIN FRACTIONS | |
| DE1173778C2 (en) | PROCESS FOR PREPARING CLEAR, STABLE SOLUTIONS OF HIGH CONTENT CHOLINE PHOSPHORIC ACID DIGLYCERIDE STARS | |
| DE1812204C3 (en) | Process for the production of purified, non-acylatable phosphatide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |